A Palo Alto life sciences investment firm founded by Srinivas Akkaraju that invests in private and public biotech companies. Its website could not be read at the time of research.
Samsara BioCapital is a Palo Alto-based life sciences investor that, according to the task hint, backs private and public biotechnology companies across therapeutic areas including oncology. At the time of research its website (samsarabiocapital.com) returned an empty page that redirected to a '/lander' address on every attempt, and no alternative primary page could be located without web search, so the firm's own description, founding year, strategy and portfolio could not be confirmed. None of the press releases or portfolio pages fetched for other entries in this file happened to name Samsara BioCapital as a co-investor, so no oncology portfolio company is cited here; any examples should be sourced from a company press release before being added.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Alpha-9 Oncology Vancouver, CA | Growth stage | radiopharma | Melanoma | Series C 2024, $175M |
| Enlaza Therapeutics La Jolla, CA, US | Startup | biotech | Series A 2024, $100M | |
| Tango Therapeutics Boston, MA, US | Public | biotech | Pancreatic ductal adenocarcinomaNon-small-cell lung cancerGlioma & glioblastoma | IPO 2021, $353M |
Shares Enlaza Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Enlaza Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Alpha-9 Oncology and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Alpha-9 Oncology and the tag vc.
Shares Alpha-9 Oncology, Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.
Shares Tango Therapeutics and the tag vc.